Skip to main content

CTAD 2026 | Nov 16, 2026 - Nov 19, 2026

Neurology

Using cutting-edge technologies, Sanofi scientists are developing targeted, potentially disease-modifying therapies for people living with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other chronic, debilitating neurological disorders. Our goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.

Available rooms
1 of 1
  • Early Pipeline